---
schema_version: "secwatch.filing_event.v1"
accession: "0000019584-26-000018"
form_type: "8-K"
ticker: "CHE"
cik: "0000019584"
company_name: "CHEMED CORP"
filed_at: "2026-07-28T20:30:32+00:00"
generated_at: "2026-07-28T20:32:36.822606+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Chemed Q2 2026: adj. EPS $6.06 (+41.9%), VITAS EBITDA +20.6%, guidance raised to $25.00-$25.75

## Summary
- Consolidated revenue $673.3M (+8.8% YoY); GAAP diluted EPS $5.13 (+43.7%); adjusted diluted EPS $6.06 (+41.9%).
- VITAS net patient revenue $443.3M (+11.9%), ADC 23,687 (+6.1%), admissions +9.0%; adjusted EBITDA $80.6M (+20.6%).
- Roto-Rooter revenue $229.9M (+3.3%), adjusted EBITDA $48.5M (flat), margin 21.1% (-77 bps).
- Full-year 2026 adjusted EPS guidance raised to $25.00-$25.75 from $24.00-$24.75; mid-point +17.8% YoY.
- Repurchased 210,000 shares for $89.8M in Q2; trailing 12-month repurchases reduced shares by ~10.5%.

## SEC filing metadata
- accession: 0000019584-26-000018
- form_type: 8-K
- ticker: CHE
- cik: 0000019584
- company_name: CHEMED CORP
- filed_at: 2026-07-28T20:30:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/19584/000001958426000018/0000019584-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/19584/000001958426000018/che-20260728x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000019584-26-000018
- JSON: https://secwatch.observer/filing/0000019584-26-000018.json
- Plain text: https://secwatch.observer/filing/0000019584-26-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.